How Much Vitamin K2 to Remove Arterial Plaque?

No dose of vitamin K2 has been proven to remove existing arterial plaque in humans. That is the honest starting point, and it matters because the question itself rests on an assumption the science has not yet confirmed. What the research does show is a plausible biological mechanism by which K2 could slow new calcium deposits in artery walls, encouraging epidemiological data linking higher K2 intake to lower cardiovascular risk, and a handful of clinical trials testing whether supplementation can stabilize or reduce coronary artery calcification. The doses being studied cluster around 360 to 720 micrograms per day of the MK-7 form, but the gap between “tested in a trial” and “proven to clear plaque” remains wide.

What K2 Actually Does in Your Arteries

The connection between vitamin K2 and arterial calcification hinges on a protein called matrix Gla protein, or MGP. MGP is one of the body’s most powerful natural inhibitors of calcification in soft tissues. But MGP only works when it has been activated through a chemical process that depends on vitamin K. Specifically, vitamin K drives a step called carboxylation: it converts inactive MGP into its active form, which then gets released into the tissue surrounding blood vessels. Once there, active MGP binds calcium and prevents it from being deposited in artery walls. It also blocks signals that would otherwise push smooth muscle cells in vessel walls to transform into bone-like cells.

¹

When vitamin K is insufficient, MGP stays in its inactive form. Inactive MGP accumulates at the boundaries between healthy vascular tissue and calcified material, essentially standing around unable to do its job.² The logic behind K2 supplementation is straightforward: supply more vitamin K, activate more MGP, and inhibit further calcium buildup. Whether that also reverses calcium already cemented into plaque is a separate and much harder question. Preventing new deposits and dissolving old ones are different biological tasks, and virtually all the trial evidence so far addresses the first.

Why MK-7, Not MK-4 or K1

Vitamin K comes in several forms. K1, or phylloquinone, is the type abundant in leafy greens. K2 is a family of compounds called menaquinones, distinguished by chain length. The two you will see discussed most are MK-4 (short chain) and MK-7 (long chain). These forms differ in how the body absorbs them, where they end up, and how long they last in the bloodstream.³

MK-7 wins the bioavailability contest by a wide margin. In a head-to-head comparison at equal doses, MK-7 reached measurable levels in the blood within hours and remained detectable for up to 48 hours. MK-4 at the same dose did not even register in the bloodstream. After a full week of daily supplementation, MK-4 still failed to raise serum levels, while MK-7 produced significant, consistent increases in every subject tested.⁴ This is why nearly every cardiovascular trial uses MK-7 rather than MK-4. It is also why K1, which is primarily used by the liver for blood clotting rather than by arteries for calcification control, has not shown the same epidemiological link to heart disease.

The Rotterdam Study, one of the most cited pieces of evidence on K2 and heart health, tracked over 4,800 people and found that those in the highest third of dietary menaquinone (K2) intake had roughly half the risk of dying from coronary heart disease compared to the lowest third. They also had significantly less severe aortic calcification. K1 intake, by contrast, showed no relationship with any cardiovascular outcome.⁵ That study was observational, so it cannot prove causation, but it helped shape the hypothesis that K2 specifically matters for arterial health.

The Doses Being Tested in Trials

If you search for a definitive dose, you will find a range rather than a single number. The trials investigating K2’s effect on arterial calcification have clustered around a few dose levels of MK-7, and none has yet delivered a conclusive verdict on plaque removal.

In hemodialysis patients, who suffer from accelerated vascular calcification and are among the populations most likely to benefit, a dose-finding study tested 360, 720, and 1,080 micrograms of MK-7 three times per week for eight weeks. All three doses reduced inactive MGP in a dose-dependent manner: 360 µg cut it by about 17%, 720 µg by about 33%, and 1,080 µg by about 46%.⁶ Lowering inactive MGP is a marker of improved vitamin K status in the vasculature, not direct proof that plaque shrank. But it confirms the mechanism is dose-responsive: more K2 activates more MGP.

A separate trial in hemodialysis patients confirmed that this population is broadly deficient in functional vitamin K and that daily K2 supplementation markedly decreased inactive MGP levels, providing what the researchers called “the rationale for intervention trials aimed at decreasing vascular calcification.”⁷

For people with severe coronary artery calcification (not on dialysis), the major ongoing trial protocol uses 720 micrograms per day of MK-7 combined with 25 micrograms of vitamin D3, for at least 24 months. That dose was selected based on a previous trial called AVADEC, which showed both efficacy in patients with high coronary calcium scores and no safety concerns.⁸ A trial in patients with type 2 diabetes is using 360 micrograms of MK-7 daily for six months, with an advanced imaging technique to track whether ongoing calcium deposits slow down or stop.⁹

So the doses in active research range from about 360 to 720 micrograms of MK-7 daily, with some dialysis studies going higher. These are far above the typical adequate intake for blood clotting (which is in the range of 90 to 120 micrograms of total vitamin K per day for adults). The cardiovascular hypothesis requires substantially more.

Slowing New Deposits Versus Reversing Old Ones

This distinction deserves its own space because it is where most popular articles get sloppy. Arterial calcification is not a simple pile of calcium sitting on a pipe wall. In mature plaque, calcium becomes structurally integrated into a complex of lipids, fibrous tissue, and cellular debris. Some cardiologists actually argue that dense, stable calcification within plaque can be protective: it stiffens the cap over the plaque and makes it less likely to rupture and cause a heart attack. What is dangerous is active, ongoing calcification in unstable plaque or in the arterial wall itself (medial calcification), which stiffens arteries and raises blood pressure.

The trials using advanced imaging are mostly looking at whether new calcium deposits can be slowed or stopped, not whether old, dense calcification gets dissolved. That is a realistic goal. Dissolving established calcification would require the body to actively resorb mineralized tissue from the vessel wall, which is a process that has not been demonstrated in human arteries with K2 supplementation. Think of it this way: K2 may help keep your arteries from getting worse, but “removing plaque” oversells what the current evidence supports.

How to Know If You Are K2 Deficient

Standard blood tests do not routinely measure vitamin K2 status. But researchers have identified a promising biomarker: desphospho-uncarboxylated MGP, usually abbreviated dp-ucMGP. This is the inactive form of that calcification-blocking protein. Higher levels of dp-ucMGP mean more of your MGP is sitting around unactivated, which correlates with worse vitamin K status in the blood vessels.

In studies of the general population, elevated dp-ucMGP has been associated with obesity, higher blood pressure, stiffer arteries, and a history of cardiovascular disease.¹⁰ In patients with stable vascular disease, high dp-ucMGP independently predicted both cardiovascular death and death from any cause.¹¹ This biomarker is not yet part of routine cardiology workups, but it may become one. If you are interested in knowing whether K2 supplementation is doing anything for you personally, dp-ucMGP is the measurement to ask about, though availability varies by lab and country.

The Vitamin D Connection

You will often see vitamin K2 and vitamin D3 discussed together, and that pairing is not just marketing. Vitamin D promotes the production of vitamin K-dependent proteins, including MGP. Without enough vitamin K to activate those proteins, vitamin D supplementation may actually leave you with more inactive MGP floating around, which is counterproductive. Research supports the idea that supplementing both vitamins together is more effective for both bone and cardiovascular health than taking either one alone.¹²

The major coronary calcification trial mentioned earlier uses this combination deliberately: 720 µg of MK-7 with 25 µg (1,000 IU) of vitamin D3 daily. If you take vitamin D supplements and are concerned about arterial calcification, ensuring adequate K2 intake is a reasonable precaution based on current understanding of the biochemistry, even while we wait for the trials to report final outcomes.

Warfarin, Statins, and Other Drug Interactions

If you take warfarin (Coumadin), the K2 question becomes considerably more complicated. Warfarin works by blocking the enzyme that recycles vitamin K, which is exactly the mechanism that keeps your blood from clotting too easily. But that same blockade also prevents MGP from being activated in your artery walls.¹³ In animal models, therapeutic doses of warfarin markedly increased vascular calcification across multiple types of arteries, while high vitamin K intake protected against it.¹⁴

This creates a genuine dilemma. Some researchers have suggested that K2 supplementation could offset warfarin’s calcification-promoting effect without disrupting its anticoagulant action, since the carboxylation that happens in artery walls is a separate process from what happens in the liver. But this idea remains unproven and potentially dangerous. Supplementing K2 while on warfarin can interfere with your INR (the blood-thinning measurement your doctor monitors), and whether reducing coronary calcification even improves outcomes in patients with atherosclerosis on warfarin remains unclear.¹⁵ If you take warfarin, do not start K2 supplementation without discussing it with your prescribing physician. If you take a direct oral anticoagulant (like apixaban or rivarelbaan), the interaction is less of a concern because those drugs do not work through the vitamin K pathway, but your doctor should still know.

Statins add another wrinkle. There is emerging evidence that statins, by inhibiting cholesterol synthesis pathways, may also impede vitamin K conversion and affect the function of vitamin K-dependent proteins.¹⁶ Whether this matters clinically or whether K2 supplementation offsets it is unknown. But it adds to the argument that people on common cardiovascular medications may have reason to pay attention to their vitamin K status.

Safety at Supplement Doses

One genuinely reassuring finding across the K2 literature is safety. No major regulatory body has set an upper intake limit for vitamin K in any form. The reasoning is that adverse effects from high doses have simply not been observed in healthy people. Safety evaluations of MK-7 specifically have confirmed this: the UK’s Expert Committee on Vitamins and Minerals set a guidance level of 1,000 µg per day, and an industry body set a tolerable upper intake level for supplements at 10,000 µg per day, both well above the doses used in cardiovascular trials.¹⁷ The WHO and FAO likewise declined to set a ceiling because of the lack of observed harm.¹⁸

The important caveat, again, is warfarin. Safety in the general population does not translate to safety in people whose blood-thinning medication depends on vitamin K metabolism being suppressed. Outside of that specific group, doses of 360 to 720 µg of MK-7 daily appear well tolerated across weeks to months of supplementation in the trials conducted so far.

Getting K2 from Food

The richest dietary source of MK-7 is natto, a Japanese fermented soybean product. A typical serving contains several hundred micrograms of MK-7, which is in the range of what clinical trials use. Certain aged cheeses, particularly Dutch varieties like Gouda and Edam, provide meaningful amounts of longer-chain menaquinones as well, though less per serving than natto. Egg yolks and organ meats (especially liver) contain MK-4.

How well your body absorbs vitamin K from food depends on the food matrix. In bioaccessibility testing, K2 from fat-containing foods like eggs and oils was more available for absorption than K2 from supplement powders. The bioaccessibility of MK-7 from natto was comparable to that of a purified MK-7 standard, suggesting natto delivers K2 efficiently.¹⁹ If you take K2 as a supplement, consuming it with a meal that includes some fat should improve absorption.

An older assumption held that gut bacteria might supply up to half of the body’s vitamin K needs. More recent research challenges this view. There is no established mechanism for absorbing vitamin K from the colon, and when dietary vitamin K is removed, deficiency develops despite gut bacteria still being present. The practical implication is that you cannot rely on your microbiome to produce enough K2 for cardiovascular purposes; you need to get it from food or supplements.²⁰

Who Might Benefit Most

Subclinical vitamin K deficiency is likely more widespread than commonly appreciated. The populations where it has been most clearly documented include people on hemodialysis, those with chronic kidney disease, patients on long-term warfarin therapy, and individuals with type 2 diabetes. But even in the general population, studies measuring dp-ucMGP consistently find that a substantial proportion of adults have levels suggesting suboptimal vitamin K status in their vasculature, even when their clotting function tests are normal. Blood clotting is the body’s first priority for vitamin K, so it is the last function to be compromised during deficiency. Arterial protection, being lower on the priority list, gets short-changed first.

People with high coronary artery calcium scores on a CT scan are the population being actively studied for K2 supplementation. If you have been told you have a calcium score above 400, the ongoing trial protocols suggest that 720 µg per day of MK-7 combined with vitamin D3 is considered a reasonable investigational dose. Whether you should start supplementing based on that information is a conversation worth having with a cardiologist, particularly one who is aware of the K2 literature, since many clinicians still think of vitamin K exclusively in terms of clotting.

The Kidney Disease Puzzle

Chronic kidney disease patients might seem like the ideal candidates for K2 supplementation, given their extreme rates of vascular calcification and documented vitamin K deficiency. But the results from trials in this population have been mixed. One explanation that has gained traction is that in uremia (the metabolic state caused by advanced kidney failure), high-density lipoproteins that normally transport K2 through the bloodstream become dysfunctional. If the delivery vehicle is broken, even large doses of K2 may not reach the artery walls where it is needed.¹⁶ This is a humbling reminder that the body is not a simple pipe that you unclog by adding the right chemical. Transport, metabolism, and local tissue conditions all matter, and they vary enormously between healthy people and those with advanced disease.

For patients on hemodialysis specifically, K2 supplementation clearly improves the biomarker (inactive MGP goes down in a dose-dependent way), but whether that translates into fewer heart attacks or slower progression of calcification over years remains an open question. Trials designed to answer that question are underway, but the kidney disease community has learned to be cautious about assuming that fixing a biomarker fixes the outcome.